Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin
Event:
ESC Congress 2024
Topic:
Venous Thromboembolism
Session:
Pearls of acute pulmonary embolism
